N. Abdulkareem

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer

Jason T. George, R. Schiff, C. Creighton, 2019, Journal of clinical medicine.

Screening of GPCR drugs for repurposing in breast cancer

R. Bond, Reid T Powell, Benny A Kaipparettu, 2022, Frontiers in Pharmacology.

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

R. Schiff, S. Vasaikar, Bing Zhang, 2022, Scientific Reports.

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

R. Schiff, S. Vasaikar, Bing Zhang, 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients

Mantasha Tabassum, Soumya G. Chikermane, N. Abdulkareem, 2024, Cardio-oncology.